



_					
Study	I^2	1	Odds Ratio (95% Crl)		
Afatinib_Cetuximab vs Afatinib					
29		<del></del>	1.0 (0.33, 3.2)		
Pooled (pair-wise)			1.0 (0.20, 5.3)		
Indirect (back-calculated)			NA		
Pooled (network)		<del>- +</del> -	1.0 (0.25, 4.1)		
Chemotherapy vs Afatini	b				
50		<del></del>	1.3 (0.34, 5.1)		
57		<del></del>	→ 3.9e+10 (3.3e-05, 4.5e+25)		
Pooled (pair-wise)	52.6%	<del></del>	2.0 (0.40, 11.)		
Indirect (back-calculated)			0.92 (0.37, 2.3)		
Pooled (network)	4.8%	+	1.1 (0.50, 2.5)		
Erlotinib vs Afatinib					
38		<del></del>	1.0 (0.49, 2.0)		
Pooled (pair-wise)		<del></del>	0.99 (0.24, 4.1)		
Indirect (back-calculated)		⊙	0.78 (0.33, 1.8)		
Pooled (network)	0.0%	<del></del>	0.83 (0.40, 1.7)		
Gefitinib vs Afatinib					
48		<del></del>	0.50 (0.19, 1.3)		
Pooled (pair-wise)		<del></del>	0.51 (0.10, 2.3)		
Indirect (back-calculated)		⊙	0.63 (0.25, 1.6)		
Pooled (network)	0.0%	<del></del>	0.59 (0.26, 1.3)		
Placebo vs Afatinib					
54		<del></del>	0.24 (0.044, 1.3)		
Pooled (pair-wise)		<b>←</b>	0.26 (0.027, 1.6)		
Indirect (back-calculated)		·····•• ···	0.74 (0.30, 1.8)		
Pooled (network)	28.9%		0.62 (0.27, 1.4)		
		0.03	30		






Study	I^2		Odds Ratio (95% Crl)		
Placebo vs Dacomitinib					
r6 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	0.0%		0.55 (0.17, 1.8) 0.56 (0.099, 2.8) 1.2 (0.40, 3.3) 0.93 (0.38, 2.2)		
Erlotinib vs DHFRi					
r18 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)		<	→ 0.96 (0.028, 33.) → 1.0 (0.021, 64.) NA → 1.2 (0.026, 43.)		
Gefitinib vs Erlotinib_ER	Ri				
72 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)			0.45 (0.10, 2.0) 0.46 (0.066, 3.0) NA 0.32 (0.093, 1.0)		
Gefitinib_ERi vs Erlotinib_ERi					
72 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)			1.6 (0.64, 4.1) 1.6 (0.36, 7.3) NA 1.6 (0.52, 5.3)		
antiangio vs Erlotinib_ar	ntiangio				
37 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	20.2%	0.03	→ 4.8 (0.65, 35.) → 4.6 (0.45, 48.) 1.3 (0.45, 3.9) 1.6 (0.70, 4.9)		







Study	I^2		Odds Ratio (95% Crl)
Placebo vs Erlotinib			
30 46 58			0.56 (0.12, 2.7) 1.8 (0.73, 4.5) - 2.6 (0.59, 11.)
Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	9.7%		1.5 (0.54, 3.7) 0.46 (0.20, 1.1) 0.76 (0.39, 1.4)
Rociletinib vs Erlotinib			J. J. (1.1.1)
53 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)		<	→ 0.99 (0.027, 36.) → 0.97 (0.017, 47.) NA → 0.96 (0.0046, 94.)
antiangio vs Erlotinib			
28 37 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	37.4% 51.2%		1.3 (0.67, 2.6) 4.9 (0.66, 37.) 1.7 (0.59, 6.2) NA 2.0 (0.86, 5.1)
Osimertinib vs Gefitinib	_Erlotinib		, ,
31 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)		0.03	2.8 (0.96, 8.3) — 2.8 (0.58, 15.) NA — 2.8 (0.75, 12.)

